The Conversation (0)
Miraculins Inc . (TSXV:MOM) has released its 2015 plans for its Scout DS diabetes screening technology. The company has identified primary sales and distribution channels it will be seeking as well as continuing to advance the Chinese SFDA approval. It will also look to appoint a medical advisory board for the Scout DS and proceed on U.S. FDA clearance submissions.
According to the press release:
The Company’s business model is to sell Scout DS® devices to established distributors in key market segments, which will then subsequently be rented or leased to their network of customers on a weekly, monthly or annual basis. These customers will utilize the devices to offer diabetes testing to the end user. The Company’s revenues will be generated from the initial sale of the devices to the distributors and, in the majority of markets, from a percentage of the ongoing rental or leasing revenue as well.
Christopher J. Moreau, president and CEO, said:
Pursuing Chinese FDA Approval, establishing full production capabilities, and establishing proof of concept for various revenue models will be the primary focus of our Scout DS® activity in 2015.
Click here to read the Miraculins Inc. (TSXV:MOM) press release
Click here to see the Miraculins Inc. (TSXV:MOM) profile.